Breaking News, Collaborations & Alliances

Merck KGaA, Hengrui Partner on Selective PARP1 Inhibitor and ADCs

Aims to develop, manufacture, and commercialize next-generation selective PARP1 inhibitor HRS-1167.

Merck KGaA, Darmstadt, Germany, entered a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. that includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167. The agreement also includes an option to an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters